Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03468335 |
|
Recruitment Status :
Recruiting
First Posted : March 16, 2018
Last Update Posted : August 7, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Locally Advanced Pancreatic Cancer Metastatic Pancreatic Cancer | Drug: Irinotecan Liposomal Injection [Onivyde] | Phase 3 |
Research hypothesis:
Patients profit from 2nd-line therapy with Nal-IRI if they also had a benefit from 1st-line treatment. Benefit from treatment (either 1st or 2nd-line) will be defined as a patient specific Time-To-Treatment Failure (TTF) which is in the upper third of the distribution of TTF values of the studied population.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 270 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Open label, single arm, multicenter phase IIIb trial |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy |
| Actual Study Start Date : | March 31, 2018 |
| Estimated Primary Completion Date : | January 31, 2020 |
| Estimated Study Completion Date : | October 31, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Single Arm
Cancer treatment for PDAC:
Treatment until progressive disease or intolerable toxicity or withdrawal of consent. |
Drug: Irinotecan Liposomal Injection [Onivyde]
Cancer treatment for PDAC:
Treatment until progressive disease or intolerable toxicity or withdrawal of consent. |
- Time to Treatment Failure of second-line treatment (TTF2) [ Time Frame: up to 6 month ]
Time-To-Treatment-Failure - (TTF2) is defined as date of signed ICF until permanent treatment discontinuation (or day of initially planned next cycle) due to progressive disease or unacceptable toxicity.
Expected increase of the TTF2 by 50% in the cohort of patients with favorable TTF1 (TTF1 high: upper third of the patient population) as compared to patients with short TTF1 (TTF low: lowest third of the patient population)
- Overall survival (OS) [ Time Frame: up to 12 month ]Survival will be calculated from the date ICF signature until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.
- Progression Free Survival (PFS) [ Time Frame: up to 12 month ]PFS is defined as the number of months from the date of first dose of 2nd-line treatment to the date of death or investigator assessed progression (by any imaging techique), whichever occurred earlier. If neither death nor progression is observed during the study, PFS data will be censored at the last valid tumor assessment.
- AEs / SAEs [ Time Frame: up to 12 month ]The Safety Population is the primary population for the evaluation of treatment administration/compliance and all safety data and will comprise all patients enrolled who received at least one dose of study medication. Patients will be analyzed according to the treatment actually received.
- Quality of Life (QoL) EORTC QLQ-C30 [ Time Frame: up to 6 month ]
Helath related Quality of Life will be evaluated with:
- EORTC QLQ-C30
- Quality of Life (QoL) EORTC QLQ-PAN26 [ Time Frame: up to 6 month ]
Helath related Quality of Life will be evaluated with:
- EORTC QLQ-PAN26
- Quality of Life (QoL) EORTC EQ-5D-5L [ Time Frame: up to 6 month ]
Helath related Quality of Life will be evaluated with:
- EORTC EQ-5D-5L
- Evaluation of time to definitive deterioration of QoL (TDD) [ Time Frame: from date of baseline Scrore until date QoL Score deterioration, assessed up to 12 month ]Time to QoL deterioration is defined as a loss of ≥ 10 points in the EORTC QLQ-C30 compared to base-line.
- Growth modulation index (GMI) [ Time Frame: up to 6 month ]The ratio of time to progression with the nth-line (TTP(n)) of therapy to the TTP(n-1) with the n-1th-line. GMI >1.33 is considered as a sign of activity in phase II trials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent including participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- Clinical indication for a 2nd-line systemic therapy according to current standard-of-care.
- Age ≥ 18 years at time of study entry
- Patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma
- Imaging of evaluable lesions within 2 weeks of inclusion (either sonography, X-ray, CT scans, MRI)
- ECOG performance status 0-2
- One line of systemic gemcitabine/Nab-paclitaxel -based therapy for advanced disease (irrespective of prior adjuvant therapy) OR Previous adjuvant gemcitabine/Nab-paclitaxel-based chemotherapy with documented progression less than 6 months after termination
- Detailed documentation of prior therapy (duration, dose-intensity, maximum toxicity, reason for discontinuation)
-
Adequate blood count, liver-enzymes, and renal function:
- neutrophil count > 1.5 x 10^6/mL
- Platelet count ≥ 100 x 10^9/L (≥100,000 per mm^3)
- AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
- bilirubin ≤1.5 ULN (<3 x ULN in patients with confirmed mechanical cholestasis)
- Creatinine Clearance CLcr ≥ 30 mL/min
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
Medical criteria:
-
Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:
- Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes
- Premalignant hematologic disorders, e.g. myelodysplastic syndrome
- Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
- Prior (<3 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial urinary bladder tumor [Ta, Tis and T1].
- Pre-existing lung disease of clinical significance or with impact on performance status
-
History or clinical evidence of CNS metastases
Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of study treament. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
- Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
- Severe non-healing wounds, ulcers or bone fractions
- Evidence of bleeding diathesis or coagulopathy
- Major surgical procedures, except open biopsy, or significant traumatic injury within 28 days prior to star of study treatment, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
- Known Gilbert-Meulengracht syndrome
- Known chronic hypoacusis, tinnitus or vertigo
- Bone marrow depression (e.g., after radiation therapy)
- Pernicious anemia and other megaloblastic anemias secondary to vitamin B12 deficiency
- Severe impairment of hepatic function
- Diarrhea
Drug related criteria:
- Medication that is known to interfere with any of the agents applied in the trial.
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- History of hypersensitivity to any of the study drugs or any of the constituents of the products.
-
Any other efficacious cancer treatment except protocol specified treatment at study start.
Safety criteria:
-
Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (urine or serum β-HCG acc. to SOC) at Screening.
Methodological criteria:
- Any experimental pretreatment for advanced disease
- Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is longer.
-
Previous enrollment in the present study (does not include screening failure).
Regulatory and ethical criteria:
- Patient who might be dependent on the sponsor, site or the investigator
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03468335
| Contact: Saskia Schulze, M.Sc. | +49(0)30 8145 344 41 | Saskia.Schulze@aio-studien-ggmbh.de |
Show 35 study locations
| Principal Investigator: | Manfred P. Lutz, Prof. Dr. | m.lutz@caritasklinikum.de |
| Responsible Party: | AIO-Studien-gGmbH |
| ClinicalTrials.gov Identifier: | NCT03468335 |
| Other Study ID Numbers: |
AIO-PAK-0216 |
| First Posted: | March 16, 2018 Key Record Dates |
| Last Update Posted: | August 7, 2019 |
| Last Verified: | August 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Second-line therapy Nal-IRI failure gemcitabine/nab-paclitaxel predictive role of 1st-line therapy |
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases |
Endocrine System Diseases Irinotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |